Hepion Pharmaceuticals, Inc. (336.MU)

1.4200 -0.0300 (-2.07%) As of 07:20PM CEST. Market open.

Hepion Pharmaceuticals, Inc.

399 Thornall Street
First Floor
Edison, NJ 08837
United States
732 902 4000
https://www.hepionpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 22

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. John T. Cavan	Interim CEO & CFO	460.05k	N/A	1958
Sharen Pyatetskaya	Director of Investor Relations	N/A	N/A	N/A
Dr. John Z. Sullivan-Bolyai	Part-Time Consultant	N/A	N/A	1948
Dr. Stephen A. Harrison FACP, M.D.	Scientific Advisory Board Chair & Consultant Medical Director	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Corporate Governance

Hepion Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.